4 completed, 2 active not recruiting, 1 recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Acute Myeloid Leukemia With Myelodysplasia-Related Changes: new trials by email Literature Review of Acute Myeloid Leukemia With Myelodysplasia-Related Changes trials Research Report on Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VYxeoS Liposomal Italian Observational Study iN the Real Practice Vyxeos liposomal - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Completed | Jazz Pharmaceuticals | 113 | 2023-12-07 | 2025-11-20 | |
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
| CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia Glasdegib, CPX-351 - Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Active not recruiting | University of California, Irvine | 30 | 2020-02-19 | 2026-07-16 |
| A Post-Marketing Observational Study of VYXEOS™ CPX-351 - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia | Completed | Jazz Pharmaceuticals | 52 | 2018-10-23 | 2020-08-05 | |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Cytarabine, Idarubicin, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 53 | 2018-04-18 | 2026-06-01 |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-07-30 |
| Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Busulfan - Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | National Cancer Institute (NCI) | 546 | 2006-11-15 | 2019-02-19 |
Leukemia, Myeloid, Acute (4) · Anemia, Refractory, with Excess of Blasts (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
CPX-351 (4) · Cytarabine (4) · Busulfan (2) · Daunorubicin (2) · Injections (2) · Antilymphocyte Serum (1) · CT-P10 (1) · Clofarabine (1) · Cord Blood Stem Cell Transplantation (1) · Cyclophosphamide (1) · Decitabine (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Idarubicin (1)
Jazz Pharmaceuticals (2) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of California, Irvine (1) · University of Southern California (1)
United States (6) · Italy (1)
Deepa Jeyakumar, MD (1) · Eunice Wang, MD (1) · Kevin Kelly, MD (1) · Warren Fingrut, MD (1) · William Blum (1)
PMID 27624549, PMID 31171508, PMID 36184192
P30CA014089 (1), R01CA211044 (1), R21CA128377 (1), U10CA031946 (1), U10CA180821 (1)